

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DKT. NO. BAYER 9-P1	SERIAL NO. 09/472,232 60/301,621
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Jacques DUMAS, et al.	
		(Use several sheets if necessary)		FILING DATE December 22, 1998	GROUP 1624 1644

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
	AA 3,823,161	07/09/74	Lesser		O I P	
	AB 5,130,331	07/14/92	Pascual			
	AC 4,808,588	02/28/89	King			
	AD 3,424,760	01/28/69	Helsley et al.			
	AE 3,424,761	01/28/69	Helsley et al.			
	AF 3,424,762	01/28/69	Helsley et al.			
	AG 4,071,524	01/31/78	Banitt			
	AH 4,111,683	09/05/78	Singer			
	AI 4,437,878	03/20/78	Acker et al.			
	AJ 4,643,849	02/17/87	Hirai et al.			
	AK 5,773,459	06/30/98	Tang et al.			
	AL 5,508,288	04/16/96	Forbes et al.			
	AM 4,062,861	12/13/77	Yukinaga et al.			
	AN 4,111,680	09/05/78	Yukinaga et al.			
	AO 4,116,671	09/26/78	Yukinaga et al.			
	AP 4,212,981	07/15/80	Yukinaga et al.			
	AQ 5,162,360	11/10/92	Creswell et al.			
	AR 4,514,571	04/30/85	Nakai et al.			
	AS 3,754,887	08/28/73	Brantley			
	AT 3,646,059	02/29/72	Brantley			
	AU 5,696,138	12/9/97	Olesen et al.			
	AV 5,780,483	7/14/98	Widdowson et al.			
	AW 4,405,644	9/20/83	Kabbe et al.			
	AX 4,473,579	9/25/84	Devries et al.			
	AY 4,526,997	7/2/85	O'Doherty et al.			
	AZ 4,468,380	8/28/84	O'Doherty et al.			
	BA 4,623,662	11/18/86	De Vries			
	BB 4,985,449	1/15/91	Haga et al.			
	BC 5,312,820	5/17/94	Ashton et al.			
	BD 4,410,697	10/18/83	Török et al.			
	BE 4,001,256	1/4/97	Callahan et al.			
	BF 5,399,566	3/21/95	Katano et al.			
	BG 5,500,424	3/19/96	Nagamine et al.			
	BH 5,597,719	1/28/97	Freed et al.			

* These references were cited on the IDS filed on July 21, 2000.

091472,232

Sheet 2 of 3

	BI	4,183,854	1/80	Crossley			
	BJ	3,828,001	8/74	Broad et al.			
	BK	4,740,520	4/88	Hallenbach et al.			
	BL	5,319,099	6/7/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
BM	EP 335156	03/11/89	European				X
BN	EP 459887	05/28/91	European				X
BO	EP 371876	11/28/89	European				X
BP	93/24458	12/9/93	WO				X
BQ	2,146,707	10/12/95	Canada				X
BR	96/40673	12/19/96	WO				X
BS	94/14801	07/07/94	WO				X
BT	94/25012	11/10/94	WO				X
BU	1,590,870	06/10/81	England				X
BV	93/18028	09/16/93	WO				X
BW	94/18170	08/18/94	WO				X
BX	DE 3305866 A1	02/19/83	Germany				X
BY	95/02591	01/26/95	WO				X
BZ	95/13067	05/18/95	WO				X
CA	95/07922	03/23/95	WO				X
CB	95/31451	11/23/95	WO				X
CC	A1 96/40675	12/19/96	WO				X
CD	JP 53 086033		Japan				
CE	JP 51 063170		Japan				
CF	97/49400	12/31/97	WO				
CG	97/49399	12/31/97	WO				
CH	96/40673	12/19/96	WO				
CI	99/00357	1/7/99	WO				
CJ	97/45400	12/4/97	WO				
CK	96/02112	3/8/90	WO				
CL	99/00370		WO				
CM	97/29743		WO				
CN	98/22432		WO				
CO	96/25157 A1	8/22/96	WO				
CP	97/40028 A1	10/30/97	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
----	---

09/472,232

Sheet 3 of 3

CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
CT	"Beilstein number" Collection, 28 pages.
CU	"Beilstein Collection," 4 pages.
CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
CX	Substructure Search, pages 1-30.
CY	Derwent World Patents Index Search, pages 20-26.
CZ	Abstract of EP 116,932
DA	Abstract of EP 676,395
DB	Abstract of EP 202,538
DC	Abstract of EP 16,371
DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
DF	Audia, James E., et al., "Potent, Selective Tetrahydro-β-carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monoecyclic Rearrangement," 1967, 2005-07.
DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
DJ	G. Daum, et al., The ins and outs of Raf Kinases, TIBS 19, November 1994, pages 474-80.
DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NRI That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors, N.Y. Academy of Science, 1993, pages 149-70.
DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.
Examiner	Date Considered